Nine Monthly Results Results Snapshot
Figures in Cr
Consolidate Nine Monthly Results
Dec'25
Net Sales
290.86
Other Operating Income
0.00
Total Operating income
290.86
Raw Material Cost
137.03
Purchase of Finished goods
0.00
(Increase) / Decrease In Stocks
-1.95
Employee Cost
36.05
Power Cost
0.00
Manufacturing Expenses
25.15
Selling and Distribution Expenses
0.00
Other Expenses
36.58
Total Expenditure (Excl Depreciation)
232.86
Operating Profit (PBDIT) excl Other Income
58.00
Other Income
8.29
Operating Profit (PBDIT)
66.29
Interest
11.36
Exceptional Items
0.00
Gross Profit (PBDT)
54.93
Depreciation
12.36
Profit Before Tax
42.56
Tax
10.12
Provisions and contingencies
0.00
Profit After Tax
32.44
Extraordinary Items
0.00
Prior Period Expenses
0.00
Other Adjustments
0.00
Net Profit
32.44
Share in Profit of Associates
0.00
Minority Interest
0.00
Other related items
0.00
Consolidated Net Profit
32.44
Equity Capital
10.14
Face Value
10.0
Reserves
0.00
Diluted Earnings per share
8.4
Operating Profit Margin (Excl OI)
19.94%
Gross Profit Margin
18.89%
PAT Margin
11.15%
Public Share Holdings (%)
0.0%
Pledged Promotor Holding (%)
0.0%
Nine Monthly Analysis Highlights
Net Sales
YoY Growth in nine months ended Dec 2025 is 8.70% vs 17.08% in Dec 2025
Consolidate Net Profit
YoY Growth in nine months ended Dec 2025 is -1.58% vs 16.10% in Dec 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in nine months ended Dec 2025 is 3.96% vs 11.92% in Dec 2025
Interest
YoY Growth in nine months ended Dec 2025 is 81.47% vs 7.93% in Dec 2025
Operating Profit Margin (Excl OI)
YoY Growth in nine months ended Dec 2025 has fallen from Dec 2025
Compare Nine Monthly Results Of Beta Drugs Ltd With
Figures in Cr
Consolidate Nine Monthly Results
Change(INR)
Change(%)
Net Sales
290.86
0
290.86
Other Operating Income
0.00
0.00
0.00
Total Operating income
290.86
0
290.86
Raw Material Cost
137.03
0
137.03
Purchase of Finished goods
0.00
0
0.00
(Increase) / Decrease In Stocks
-1.95
0
-1.95
Employee Cost
36.05
0
36.05
Power Cost
0.00
0
0.00
Manufacturing Expenses
25.15
0
25.15
Selling and Distribution Expenses
0.00
0
0.00
Other Expenses
36.58
0.00
36.58
Total Expenditure (Excl Depreciation)
232.86
0
232.86
Operating Profit (PBDIT) excl Other Income
58.00
0.00
58.00
Other Income
8.29
0
8.29
Operating Profit (PBDIT)
66.29
0
66.29
Interest
11.36
0
11.36
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
54.93
0
54.93
Depreciation
12.36
0
12.36
Profit Before Tax
42.56
0
42.56
Tax
10.12
0
10.12
Provisions and contingencies
0.00
0
0.00
Profit After Tax
32.44
0
32.44
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0.00
0
0.00
Other Adjustments
0.00
0
0.00
Net Profit
32.44
0
32.44
Share in Profit of Associates
0.00
0
0.00
Minority Interest
0.00
0
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
32.44
0
32.44
Equity Capital
10.14
0
10.14
Face Value
10.00
0
0.00
Reserves
0.00
0
0.00
Gross Profit Margin
18.89%
0%
0.00
18.89%
PAT Margin
11.15%
0%
0.00
11.15%
Public Share Holdings (%)
0.00%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0%
0.00
0.00%
Nine Monthly - Net Sales
Net Sales 290.86 Cr
in Dec 2025Figures in Cr
YoY Growth in nine months ended Dec 2025 is 8.70% vs 17.08% in Dec 2025
Nine Monthly - Consolidate Net Profit
Consolidate Net Profit 32.44 Cr
in Dec 2025Figures in Cr
YoY Growth in nine months ended Dec 2025 is -1.58% vs 16.10% in Dec 2025
Nine Monthly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 58.00 Cr
in Dec 2025Figures in Cr
YoY Growth in nine months ended Dec 2025 is 3.96% vs 11.92% in Dec 2025
Nine Monthly - Interest
Interest 11.36 Cr
in Dec 2025Figures in Cr
YoY Growth in nine months ended Dec 2025 is 81.47% vs 7.93% in Dec 2025
Nine Monthly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 19.94%
in Dec 2025Figures in %
YoY Growth in nine months ended Dec 2025 has fallen from Dec 2025
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
